Grace Therapeutics

Company snapshot

Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company’s novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery – all which could help to increase

• 29 active pipeline program(s) linked via ClinicalTrials.gov.
• 34 US patent(s) indexed to this assignee profile.
• 29 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Grace Therapeutics. Not investment advice.

• Peer + 0 momentum

  Teva Pharma

  TA overlap score 40

• Peer + 0 momentum

  Arrowhead Pharmaceuticals Ireland

  TA overlap score 32.6

• Peer + 0 momentum

  Amneal Pharma Europe

  TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for Grace Therapeutics.

1. Jun 8, 2026 Clinical update

   Zinc gluconate — Unknown

2. Jun 8, 2026 Clinical update

   Lipid Lowering Medication — Phase 2

3. Jun 8, 2026 Clinical update

   Ketamine — Phase 2

4. Jun 8, 2026 Clinical update

   Ketamine (Ketalar) — Phase 1

5. Jun 8, 2026 Clinical update

   Ketamine (Ketalar) Dose Level 1 — Phase 1

View all clinical trial activity →

• What is Grace Therapeutics?

  Grace Therapeutics is a pharma organization headquartered in Laval, CA. It trades on NYSE under ticker GRCE. Primary therapeutic focus areas include Hypertriglyceridemia, Asthma, Pain, Superficial Basal Cell Carcinoma, Senile Plaques. NovaPharmaNews links 29 clinical program(s),

• Is Grace Therapeutics publicly traded?

  Yes. Grace Therapeutics is listed with ticker GRCE on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Grace Therapeutics develop or market?

  We link 37 drug profile(s) where Grace Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/grace-therapeutics#company-drugs.

• What are the latest developments for Grace Therapeutics?

  In the last 12 months our linked public records show 29 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Grace Therapeutics focus on?

  Grace Therapeutics focuses on Hypertriglyceridemia, Asthma, Pain based on our analysis of their pipeline programs and drug development activities.